Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
An open-label, fixed-sequence, single-centre phase I study to assess the effect of ketoconazole on the pharmacokinetics of AZD5069 after oral administration of a single dose AZD5069 to healthy male volunteers
Age
18–50
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Healthy male volunteers aged 18 to 50 years (inclusive).
Veins suitable for cannulation or repeated venipuncture.
Healthy volunteers with neutrophil counts within the laboratory normal reference range at Screening
Body mass index (BMI) ≥18.0 and ≤30.0 kg/m2 calculated from height and weight at screening; minimum weight 50 kg and maximum weight 100 kg.
Non-smokers or ex-smokers with no smoking history for the last 3 months prior to screening and a smoking history of less than 10 pack years (1 pack year = tobacco consumption corresponding to 20 cigarettes smoked per day for 1 year) at screening.
You may not be if
Healthy volunteers with latent tuberculosis as suggested by their history and judged by the Investigator
Healthy volunteers who belong to a high-risk group for HIV infection.
Known or suspected history of significant drug abuse as judged by the Investigator.
History of alcohol abuse or excessive intake of alcohol as judged by the Investigator.
Plasma donation within 1 month of screening or any blood donation/blood loss \>500 mL during the 3 months and/or 1350 mL within the 12 months prior to screening.
Clareo Health | Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.
